Is AMGN Overvalued? DCF Says Worth $189

gurufocus.com · 2026-10-19

On October 19, 2026, we conducted a DCF analysis for Amgen Inc (AMGN) amidst a strong price performance, with the stock appreciating significantly over the past

TickrTrends take: Amgen trades at a valuation that TickrTrends currently assesses as overvalued within the Healthcare sector. A discounted cash flow analysis suggests a fair value of $189, which provides a specific benchmark for comparing against current market pricing. Investors focused on valuation metrics should monitor whether the stock moves toward this DCF-derived level or if the market maintains a premium to this fundamental estimate.

Read the full story at gurufocus.com →